Hamid Khoja - 15 Sep 2026 Form 4 Insider Report for FibroBiologics, Inc. (FBLG)

Reporting relationship: Chief Scientific Officer
Issuer ticker: FBLG
Reported as of: 15 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Sep 2026, 19:26:30 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ruben A. Garcia, by Power of Attorney

Key filing fact

Hamid Khoja filed Form 4 for FibroBiologics, Inc. (FBLG) on 15 Sep 2026.

Key facts

This page summarizes Hamid Khoja's Form 4 filing for FibroBiologics, Inc. (FBLG).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Sep 2026, 19:26.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002010662 Primary reporting owner

Khoja Hamid

Relationship: Chief Scientific Officer
Address: C/O FIBROBIOLOGICS, INC., 9350 KIRBY DRIVE., SUITE 300, HOUSTON
Signature: /s/ Ruben A. Garcia, by Power of Attorney
Signature date: 15 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FBLG transaction

Common Stock

Award

Transaction value
Shares: +298,508
Change %: +9746%
Price: $1.68^*
Shares after: 301,571
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FBLG transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +298,508
Change %
Price
Shares after: 298,508
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 298,508
Exercise price: $1.55
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering").

Footnote F2

Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675.

Footnote F3

The warrants are exercisable at any time until they expire.

SEC remarks

Exhibit 24 Power of Attorney